

National Traceability Pilot for Pharmaceutical Products

COLOMBIA









- Background & Objectives
- Scope & Schedule
- The process and model
- Key conclusions & Next steps







Background & Objectives

LAW 1122, 2007

ARTICLE 34 Literal d)

INVIMA is responsible of ensuring the identification of medicines at any stage of the supply chain, from production to the final consumer, through a marking technology, in order to prevent counterfeiting, adulteration, maturity and smuggling.





Background & Objectives

INVIMA is developing the pilot with the support of GS1 Colombia, in order to establish if the technology that we used, is the appropriate one for the national conditions.

The pilot is based on the application of international standards in accordance with the recommendations given by "Universidad Nacional",



To consider:



• MEDICINES

GROUP 1

GROUP 2

GROUP 3

GROUP 4

• ACTORS

PRODUCERS

IMPORTERS

WHOLESALER AND

RETAIL

DISTRIBUTORS

PHARMACEUTICAL

SERVICES

DRUGSTORE CHAINS

Large Cities

Border towns

 Inaccessible areas

• GEOGRAPHICAL ZONES

INSTITUTIONAL

• DISTRIBUTION CHANNEL



To develop with healthcare supply chain actors a traceability pilot for pharmaceutical products using international standards, that allows to know the requirements to deploy a national traceability system.





Specific objectives



- ✓ Identify improvement opportunities in the proceses related to traceability.
- Design and validate a traceability model according to local requirements.
- Develop a prototype system that can be tested in a real operation.
- Collect learnings and recommendations
- Establish the technical and functional requirements to build the web platform to be used.
- ✓ Recommend a road map for implementation.





Scope & schedule





Scope



Traceability from shipping in the Lab to reception at the pharmacy





Together with the inspection process performed by INVIMA



Participants











requiere lo mejor.







Wholesalers: Dromayor, Axa, Detal, Copidrogas, Copservir, Eticos Serrano Gomez, Colsubsidio, Cafam, y el Fondo Rotatorio Norte de Santander.




















Hospitals: Asisfarma (2 Pharmaceutical Services), Clinica Hemato Oncologos, Clinica Vida, Clinica Stella Maris y Clinica Offimedicas Norte

Pharmacies: 20 Pharmacies and 13 Independent Drugstores





Medicines Involved



- TRASTUZUMAB
- RITUXIMAB
- BORTEZOMIB
- DASATINIB
- INFLIXIMAB
- IXABEPILONE
- LEVOFLOXACIN
- METOPROLOL
- OXYCODONE
- METHADONE
- DICLOFENAC
- SILDENAFIL





Schedule



JUNE-AUGUST 2012

SEPT-OCTOBER 2012 **NOV-JANUARY** 2013

FEBRUARY -**MARCH 2013**

Kick Off & Preparation

-Call action confirmation from each participant

- -Gathering information and document to participate in requirements
- -Design and deployment of |-Installation of printing the traceability prototype software and hardware and platform

Training & Assembly

- -Develop of protocol the pilot.
- 2d barcode readers-
- -Training to all participants about traceability using GS1 Standards and the protocol.
- -Testing of the prototype traceability platform

Deployment


- -Start marking and shipping of medicines involved in the Lab
- -Start all participants to report to the platform information about receptions and shipping.


Analysis of Results



The process & model










Starting Point





SERIALIZATION


Label TTL 1.25 x 0.5" (1cm x 3.15cm)






Our guide!







STL

- + Despacho
- + Recepcion
- **♦ Productos**
- → Consultas
 - ▶ Consulta Trazabilidad

Consulta de Trazabilidad

Seleccione el criterio de búsqueda e ingrese el valor indicado.

Informacion de Producto

Ingrese Lectura de DataMatrix

01076401280141951714053110lot123p

Agregar

GTIN

Fecha Vencimiento lote

Lote

Serial

lot123pru

140531

07640128014195

12345

Buscar



	Informacion del Producto			
GTIN	07640128014195]		
CUM	19903070-1]		
LOTE	lot123pru]	Herceptin*	
FECHA DE VENCIMIENTO	5/31/2014 12:00:00 AM	無	travitzumah 440 mg Parat ali makapara seksika para bersika para seksika parat di parat bersika par	Mayor State
DESCRIPCION	HERCEPTIN ® POLVO LIOFILIZADO PARA INFUSION 440 MG	Non-Administration and appropriate to the control of the control		
MARCA	HERCEPTIN	To an an		
FORMA FARMACEUTICA	POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE		I Was Ben	
CANTIDAD CONTENIDA	1			
REGISTRO SANITARIO	INVIMA 2010 M-14188-R1]		
CONCENTRACION	A]		
PRESENTACION	CAJA CON 1 VIAL DE 50 ML CON 440 MG DE LIOFILIZADO + 1 VIAL CON 20 ML DE SOLVENTE]		
PRINCIPIO ACTIVO	TRASTUZUMAB]		
CANTIDAD	440]		
UNIDAD DE MEDIDA	MG]		

Información de Trazabilidad

Fecha	Factura	Despacho	Orden	Origen	Destino	Función
9/20/2012 10:35:24 PM	FACp001	DESP0001	PED90001	ROCHE	DROMAYOR	Despacho
9/20/2012 10:36:06 PM				DROMAYOR		Recibo
9/20/2012 11:25:48 PM	FACp003	DESP0003	PED90003	DROMAYOR	DROGUERÍA LIFE	Despacho



Acta de Recepción

Consulta de Facturas. Puede verificar los productos asociados a una factura que le haya sido despachado previamente para realizar el proceso de recibo.

Observacion: El acta de recepcion solo se genera si ha sido recibida el 100% de todos los productos de esta en el sistema.

Seleccione Origen Seleccione Factura u Orden Consultar Acta

NUMERO DE LA FACTURA REMISORIA: 451590

NUMERO DEL DESPACHO REMISORIA: 8007552533

NUMERO DEL PEDIDO REMISORIA: 5006863622

FECHA DE DESPACHO: 13/12/2012 03:57:30

FECHA DE RECEPCIÓN: 12/15/2012

NOMBRE DEL PROVEEDOR / BRISTOL MYERS SQUIBB S.A. / Sin

DIRECCION: Direccion

NOMBRE DEL CLIENTE / DIRECCION: HEMATO ONCOLOGICO S.A. / Sin Direccion

Cantidad	GTIN	CUM	Nombre	Forma Farmaceutica	Concentracion	Presentacion	Cantidad Contenida	Lote	Fecha de Vencimiento Lote	Registro INVIMA	Laboratorio / Proveedor
4	08027950150038	20001660-1	IXEMPRA® 15 MG POLVO SOLUCION INYECTABLE	POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE	A	KIT-ESTUCHE CON SISTEMA DE DOS VIALES DE VIDRIO TIPO I, EL PRIMERO CONTENIENDO EL POLVO CON IXABEPILONA 15 MG/VIAL Y EL SEGUNDO	1 U	2J00736	5/15/2014 12:00:00 AM	INVIMA 2008M- 0009025	BRISTOL MYERS SQUIBB S.A.
4	08027950150045	20001858-1	IXEMPRA® 45 MG POLVO PARA SOLUCION INYECTABLE	POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE	A	KIT-ESTUCHE CON SISTEMA DE DOS VIALES DE VIDRIO TIPO I,EL PRIMERO CONTENIENDO EL POLVO CON IXABEPILONA 45 MG/VIAL Y EL SEGUNDO E	1 U	2J00743	3/30/2014 12:00:00 AM	INVIMA 2008M- 0009026	BRISTOL MYERS SQUIBB S.A.



Inspection, Surveillance and Control Model







Static Information:

Data sheet, sanitary registration, brand, brand owner, etc.

Dynamic Information:

From, To, Lot, Expiration date, serial, etc..







Key conclusions & Next steps





Figures & Results



- ✓ 205 deliveries
- √ 31.788 units
- ✓ 25 Pharmaceutical Presentations
- ✓ 12 Active ingredients
- ✓ 100% Effectiveness of reception and dispensation at hospitals
- ✓ 94% Effectiveness of reception at wholesalers*
- ✓ 84% Effectiveness of reception at pharmacies*





Findings



- ✓ There was total acceptance from the headquarters of the Labs involved in the project.
- ✓ The model matches with Lab brands protecting systems.
- ✓ The proposed system enables us to accomplish regulations such as the Technical Reception Document
- ✓ The platform allowed us to identify the interchange of a medicine between 2 hospitals, it should be considered by the model to be implemented.



Findings



- ✓ Using GS1 eCom messages as DESADV and RECADV, will facilitate the implementation of the model proposed.
- ✓ Not only does the system need to use GTIN to identify medicines, but also the GLN to identify the locations
- ✓ The POS system at pharmacies must be synchronised with the traceability system.





Key Conclusions



- All participants agree to use the GS1 Datamatrix Code to implement the traceability system
- Serialization: helps to detect issues with the origin and exact destination of the pharmaceutical products, but it will be implemented gradually starting with high cost and specifically controlled medicines.
- Direct marking on the product implies reviewing the speed of the production line, packaging material and costs for all actors.



Next Steps



- Considering the results of the pilot, INVIMA will write a regulation proposal to the Healthcare Ministry on the 4Q of 2013
- To start a stage with manufacturers and distributors to size the capacity and costs to deployment the traceability system





Leonel Pava

Communities Development Manager

GS1 Colombia

Avda. El Dorado 70 - 16

T + 57 1 4270999

E lpava@gs1co.org

W www.gs1co.org

